Cahill Represents Initial Purchaser in $500 Million Offering for Catalent Pharma Solutions, Inc.
Date: 06/27/19
Cahill represented the initial purchaser in connection with a Rule 144A offering of $500,000,000 aggregate principal amount of 5.00% senior notes due 2027 for Catalent Pharma Solutions, Inc., a company involved in technology and development for drugs, biologics and consumer health products. Proceeds from the offering were used to repay certain existing indebtedness and for general corporate purposes.